Metabolic and endocrine diseases – is our approach always rational?
Authors:
Ludmila Brunerová 1; Jana Urbanová 1; Jan Brož 2
Authors‘ workplace:
Interní klinika FNKV a 3. LF UK Praha
1; Interní klinika FN Motol a 2. LF UK Praha
2
Published in:
Vnitř Lék 2021; 67(7): 399-403
Category:
Main Topic
Overview
Choosing wisely in metabolic and endocrine diseases shows the inutility of some, in clinical practice often used, ways of management. In diabetology, the routine recommendation for selfmonitoring of type 2 diabetic patients not treated with insulin represents a contraversial issue. On the contrary, there is a consensus on rational targets of glycemic control in elderly frailty patients with limited life expectancy. In endocrinology (thyroid diseases), the iniciative fights against the overuse of some laboratory examinations and ultrasonography. The recommendations on the rational indications of densitometry are discussed. In conclusion, these recommendations within Choosing wisely initiative of different professional associations usualy arise from expert views, supported by relevant clinical studies. They represent a challange to think over rational management of care.
Keywords:
diabetology – hyperlipidemia – Endocrinology – Choosing wisely
Sources
1. Redberg Grady RF. Less is More: how less health care can result in better health Arch Intern Med 2010; 170(9): 749–750.
2. American Academy of Family Physicians. Choosing wisely 2018. https://www.choosingwisely. org/clinician‑lists/ aafp‑daily‑home‑glucose‑monitoring‑for‑patients‑with‑type- 2-diabetes/
3. Endocrine Society. Five Things Physicians and Patients Should Question. Poslední revize 2021. https://www.choosingwisely.org/societies/endocrine‑society/
4. Canadian Society of Endocrinology and Metabolism. Five Things Physicians and Patients Should Question. Poslední revize 2020. https://choosingwiselycanada.org/endocrinology‑and‑metabolism/
5. Zhu H, Zhu Y, Leung S. Is self‑monitoring of blood glucose effective in improving glycaemic control in type 2 diabetes without insulin treatment: a meta‑analysis of randomised controlled trials. BMJ Open 2016;6:e010524. doi: 10.1136/bmjopen-2015-010524
6. Yingqi Xu, David Hsien Yung Tan, Joyce Yu‑Chia Lee. Evaluating the impact of self‑monitoring of blood glucose frequencies on glucose control in patients with type 2 diabetes who do not use insulin: A systematic review and meta‑analysis Int J Clin Pract 2019; 73(7): e13357. doi: 10.1111/ijcp.13357.
7. Satoshi Ida, Ryutaro Kaneko, Kazuya Murata. Utility of Real‑Time and Retrospective Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus: A Meta‑Analysis of Randomized Controlled Trials. J Diabetes Res 2019; 15:4684815. doi: 10.1155/2019/4684815.
8. Sarah Puhr, Peter Calhoun, John B Welsh, Tomas C Walker. The Effect of Reduced Self‑Monitored Blood Glucose Testing After Adoption of Continuous Glucose Monitoring on Hemoglobin A1c and Time in Range. Diabetes Technol Ther 2018; 20(8): 557–560. doi: 10.1089/dia.2018.0134.
9. Rafael Vaz Machry, Dimitris Varvaki Rados, Guilherme Ribeiro de Gregório, Ticiana Costa Rodrigues. Self‑monitoring blood glucose improves glycemic control in type 2 diabetes without intensive treatment: A systematic review and meta‑analysis. Diabetes Res Clin Pract 2018; 142: 173–187. doi: 10.1016/j.diabres.2018. 05. 037.
10. Davidson MB, Castellanos M, Kain D, Duran P. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med 2005; 118: 422–425.
11. Farmer A, Wade A, Goyder E, Yudkin P, French D, Craven A, Holman Rury, Kinmonth AL, Neil A. Impact of self monitoring of blood glucose in the management of patients with non‑insulin treated diabetes: open parallel group randomized trial. BMJ 2007; 335: 132–140.
12. O’Kane MJ, Bunting B, Copeland M, Coates VE; ESMON study group. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomized controlled trial. BMJ. 2008; 336: 1174–1177.
13. Young LA, Buse JB, Weaver MA et al. Glucose Self‑monitoring in Non–Insulin‑Treated Patients With Type 2 Diabetes in Primary Care Settings: A Randomized Trial. JAMA Intern Med 2017; 177(7): 920–929. doi:10.1001/jamainternmed.2017.1233.
14. Diabetes Technology: Standards of Medical Care in Diabetes–2021. American Diabetes Association. Diabetes Care 2021 Jan; 44(Supplement 1): S85–S99. https://doi.org/10.2337/ dc21-S007).
15. Česká diabetologická společnost. Doporučený postup péče o diabetes mellitus 2. typu. Za ČDS: J. Škrha, T. Pelikánová, M. Prázný, M. Kvapil Revize ze dne: 31. 5. 2020. Dostupné online: https://www.diab.cz/standardy.
16. American Geriatrics Society. Ten Things Clinicians and Patients Should Question. Poslední revize 2021. https://www.choosingwisely.org/societies/american‑geriatrics‑society/
17. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole CD. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010; 375(9713): 481–489. doi: 10.1016/S0140-6736(09)61969-3.
18. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 Diabetes. N Eng J Med 2008; 258(24): 2545–2559.
19. The Action to Control Cardiovascular Risk in Diabetes Study Group. Long‑term effects of intensive glucose lowering on cardiovascular outcomes. N Eng J Med 2011; 364(9): 818–828.
20. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, Korytkowski MT, Nunshi MN, Odegard PS, Pratley RE, Swift CS. Diabetes in older adults: A consensus report. J Am Geriatr Soc. 2012 Oct; 60(12): 2342–2356.
21. Kosjerina, Vanja et al. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register‑based study.The Lancet Healthy Longevity 2021; https://doi. org/10.1016/S2666-7568(21)00170-7.
22. AMDA – The Society for Post‑Acute and Long‑Term Care Medicine™Fifteen Things Physicians and Patients Should Question. Poslední revize 2021. https://www.choosingwisely. org/wp‑content/ uploads/2015/02/AMDA_2020-Updates_Draft-2.pdf
23. Hirsch IB. Sliding scale insulin—time to stop sliding. JAMA 2009; 301(2): 213–214.
24. Golightly LK, Jones MA, Hamamura DH, Stolpman NM, McDermott MT. Management of diabetes mellitus in hospitalized patients: efficiency and effectiveness of sliding‑scale insulin therapy. Pharmacotherapy 2006; 26(10): 1421–1432.
25. American Society for Clinical Pathology. Choosing wisely. https://www.choosingwisely. org/clinician‑lists/ american‑society‑clinical‑pathology‑expanded‑lipid‑panels‑to‑screen‑for‑cardiovascular‑disease
26. Frank L J Visseren, François Mach, Yvo M Smulders, David Carballo, Konstantinos C Koskinas, Maria Bäck, Athanase Benetos, Alessandro Biffi, José‑Manuel Boavida, et al, ESC Scientific Document Group. ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC), European Heart Journal 221; 42 (34): 3227–3337, https://doi.org/10.1093/eurheartj/ehab484.
27. AMDA – The Society for Post‑Acute and Long‑Term Care Medicine. Choosing wisely. Poslední revize. https://www.choosingwisely.org/clinician‑lists/ amda‑lipid‑lowering‑medications/.
28. Dalleur O, Spinewine A, Henrard S, Losseau C, Speybroeck N, Boland B. Inappropriate prescribing and related hospital admissions in frail older persons according to the STOPP and START criteria. Drugs Aging. 2012; 29(10): 829–837.
29. Schiattarella GG, Perrino C, Magliulo F, Ilardi F, Serino F, Trimarco V, Izzo R, Amato B, Terranova C, Cardin F, Militello C, Leosco D, Trimarco B, Esposito G. Statins and the elderly: recent evidence and current indications. Aging Clin Exp Res. 2012 Jun; 24(3 Suppl):47–55.
30. Maraldi C, Lattanzio F, Onder G, Gallerani M, Bustacchini S, De Tommaso G, Volpato S. Variability in the prescription of cardiovascular medications in older patients: correlates and potential explanations. Drugs Aging 2009 Dec; 26 Suppl 1: 41–51.
31. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357: 266–281.
32. Holick MF, Binkley NC, Bischoff‑Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul; 96(7): 1911–1930.
33. Sattar N, Welsh P, Panarelli M, Forouchi NG. Increasing requests for vitamin D measurement: Costly, confusing, and without credibility. Lancet [Internet]. 2012 Jan cited 2012 Oct 12]; 379: 95–96.
34. Lefevre ML. Screening for Thyroid Dysfunction: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine 2015 May; 162(9): 641.
35. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah‑Pollack R, Singer PA, Woeber KA. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012; Sep 11: 1–207.
36. Garber JR, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract 2012 Nov‑Dec; 18(6): 988–1028.
37. de Carvalho GA, Paz‑Filho G, Mesa Junior C, Graf H. Management of endocrine disease: Pitfalls on the replacement therapy for primary and central hypothyroidism in adults. Eur J Endocrinol 2018; 178(6): R231–R244.
38. American College of Radiology.Ten Things Physicians and Patients Should Question. Poslední revize 2019. https://www.choosingwisely.org/societies/american‑college‑of‑radiology/.
39. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide Thyroid‑Cancer Epidemic? The Increasing Impact of Overdiagnosis. N Engl J Med. 2016; 375(7): 614–617. doi: 10.1056/NEJMp1604412. PubMed PMID: 27532827.
40. Hoang JK, Langer JE, Middleton WD, Wu CC, Hammers LW, Cronan JJ, Tessler FN, Grant EG, Berland LL. Managing incidental thyroid nodules detected on imaging: white paper of the ACR Incidental Thyroid Findings Committee. J Am Coll Radiol. 2015; 12(2):143–150. doi: 10.1016/j.jacr.2014. 09. 038.
41. Ahmed S, Horton KM, Jeffrey RB Jr, Sheth S, Fishman EK. Incidental thyroid nodules on chest CT: Review of the literature and management suggestions. AJR Am J Roentgenol. 2010;195(5):1066-71. doi: 10.2214/AJR.10.4506.
42. Tanpitukpongse TP, Grady AT, Sosa JA, Eastwood JD, Choudhury KR, Hoang JK. Incidental thyroid nodules on CT or MRI: Discordance between what we report and what receives workup. AJR Am J Roentgenol. 2015; 205(6): 1281-1287. doi: 10.2214/AJR.15.14929.
43. Bryan R. Haugen, Erik K. Alexander, Keith C. Bible, Gerard M. Doherty, Susan J. Mandel, Yuri E. Nikiforov, Furio Pacini, Gregory W. Randolph, Anna M. Sawka, Martin Schlumberger, Kathryn G. Schuff, Steven I. Sherman, Julie Ann Sosa, et al. Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016. 1-133. http://doi.org/10.1089/thy.2015.0020.
44. Maria Papaleontiou, Debbie W Chen, Mousumi Banerjee, David Reyes‑Gastelum, Ann S Hamilton, Kevin C Ward, Megan R Haymart. Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study. Thyroid. 2021 Apr 23. doi: 10.1089/thy.2021.0033.
45. Laura Y. Wang, Andrew W. Smith, Frank L. Palmer, R. Michael Tuttle, Azhar Mahrous, Iain J. Nixon, Snehal G. Patel, Ian Ganly, James A. Fagin, and Laura Boucai. Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate‑Risk Patients with Differentiated Thyroid Carcinoma. Thyroid. Mar 2015.300- 307. http://doi.org/10.1089/thy.2014.0287.
Další literatura u autorky a na www.casopisvnitrnilekarstvi.cz
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2021 Issue 7
Most read in this issue
- Hereditary hemorrhagic telangiectasia (Osler‑Weber‑Rendu syndrome) – Part II. Pharmacological therapy and international guidelines for the therapy 2020
- Appropriate and inappropriate therapies of implantable cardioverter‑defibrillators
- Metabolic and endocrine diseases – is our approach always rational?
- First zero contrast PCI guided by intracoronary ultrasound in the Czech Republic